| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Naftazone targets vascular endothelial cells and blood vessels. It protects blood vessels, increases venous tonicity and capillary resistance. The compound's molecular mechanism involves its binding interactions with biomolecules and its ability to inhibit or activate enzymes. The reduction of its quinone-semicarbazone moiety by potassium borohydride is a key step in its mechanism of action. Naftazone is a naphthoquinone derivative with vasoprotective and hemostatic properties.
|
|---|---|
| ln Vitro |
In mouse cerebellar synaptosomes, naftazone (0.5-50 μM; 1 h) decreases glutamate release[1].
In vitro, Naftazone accelerates human saphenous vein endothelial cell proliferation at concentrations which did not alter the hemostatic balance. It reduces glutamate release from mouse cerebellum synaptosomes at 0.5-50 μM for 1 hour. The compound is a naphthoquinone derivative with vasoprotective activity. Detailed in vitro data are available in the primary literature. Naftazone is a valuable tool for studying vascular protection and hemostasis. |
| ln Vivo |
The glutamate content of the cerebrospinal fluid is impacted by naftazone (10 and 100 mg/kg; po once daily for 15 days)[1]. Rats' platelet function is impacted by naftazone (50 mg/kg; intraperitoneally once daily for five days)[2].
In vivo, Naftazone is used as a vasoprotectant drug for hemostasis. It protects blood vessels, increases venous tonicity and capillary resistance, and improves lymphatic and venous circulation. The compound has been studied at oral doses of 10 and 100 mg/kg once per day. Naftazone is used for the research of venous insufficiency. It is a novel and potent vasoprotectant. |
| Enzyme Assay |
In vitro assays for Naftazone typically measure endothelial cell proliferation and vascular protection. Human saphenous vein endothelial cells are cultured in appropriate medium. Cells are seeded in multi-well plates and treated with Naftazone at various concentrations (0.1-100 μM) for 24-72 hours. Cell proliferation is assessed by BrdU incorporation or MTT assay. Glutamate release assays use mouse cerebellum synaptosomes treated with Naftazone (0.5-50 μM) for 1 hour, with glutamate levels measured by fluorometric or colorimetric methods. Controls include vehicle and known vasoprotective agents.
|
| Cell Assay |
For cell-based assays, human saphenous vein endothelial cells or other vascular cell lines are cultured in appropriate medium. Cells are seeded in multi-well plates and treated with Naftazone at various concentrations for 24-72 hours. Cell proliferation is assessed by BrdU incorporation, MTT assay, or CellTiter-Glo. Endothelial barrier function may be assessed by permeability assays. Cell viability is assessed by standard assays. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
Animal/Disease Models: Male rats[1]
Doses: 10 and 100 mg/kg Route of Administration: po (oral gavage); 10 and 100 mg/kg once per day; for 15 days Experimental Results: Dramatically decreased glutamate content in cerebro spinal fluid of rats. Animal/Disease Models: Wistar rats[2] Doses: 50 mg/kg Route of Administration: intraperitoneal (ip)injection ; 50 mg/kg one time/day for 5 days Experimental Results: decreased the height of platelet aggregation induced by ADP, Dramatically increased the platelet disaggregation induced by collagen and decreased fibrinogen binding to 2.5 or 5 μM ADP-stimulated platelet. In vivo, Naftazone is typically administered orally to rodents at doses of 10-100 mg/kg once per day. The compound is formulated in a suitable vehicle. For venous insufficiency models, animals are treated with Naftazone at various regimens. Endpoints include venous tone measurement, capillary resistance assessment, and histological evaluation of vascular tissue. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional animal care guidelines. |
| ADME/Pharmacokinetics |
Naftazone (MW 215.21, C₁₁H₉N₃O₂) is a naphthoquinone derivative. The compound is also known as Etioven. Detailed pharmacokinetic parameters are not extensively reported in publicly available sources. The compound is typically stored at room temperature. Further ADME studies are needed to fully characterize its pharmacokinetic profile. The compound is for research purposes.
|
| Toxicity/Toxicokinetics |
Toxicology data for Naftazone are limited in publicly available sources. As a vasoprotectant, potential effects on hemostasis and vascular function should be considered. The compound is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions.
|
| References | |
| Additional Infomation |
Naftazone belong to the naphthalene family of compounds.
Naftazone (Etioven) is a research-grade naphthoquinone derivative vasoprotectant for studying venous insufficiency and hemostasis. Its primary applications include vascular biology, hemostasis research, and drug discovery. The compound is not approved for clinical use in many countries. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves vascular protection, increased venous tonicity, and improved circulation. |
| Molecular Formula |
C11H9N3O2
|
|---|---|
| Molecular Weight |
215.212
|
| Exact Mass |
215.069
|
| CAS # |
15687-37-3
|
| PubChem CID |
71688
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.4g/cm3
|
| Index of Refraction |
1.678
|
| LogP |
2.011
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
16
|
| Complexity |
293
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
NC(N/N=C1\C=CC2=CC=CC=C2C\1=O)=O
|
| InChi Key |
AGSIRJFXAANBMW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H9N3O2/c12-11(16)14-13-9-6-5-7-3-1-2-4-8(7)10(9)15/h1-6,15H,(H2,12,16)
|
| Chemical Name |
(1-hydroxynaphthalen-2-yl)iminourea
|
| Synonyms |
C05CX02 Etioven Naftazone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6466 mL | 23.2331 mL | 46.4662 mL | |
| 5 mM | 0.9293 mL | 4.6466 mL | 9.2932 mL | |
| 10 mM | 0.4647 mL | 2.3233 mL | 4.6466 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
